In addition, there was no statistically significant change in NGAL with FDI treatment, similar to the IRON-TURTLE trial using a dose of 1000 mg of ferric carboxymaltose in patients with heart failure and CKD and correlating with in vivo and in vitro evidence relevant to third-generation i.v. iron compounds.5 The gene discussed is LCN2; the disease is heart failure.